Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23,145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
Sharma A, Marques P, Neuen BL, Fletcher RA, Slee A, Rapattoni W, Ang FG, Arnott C, Levin A, Verma S, Perkovic V, Mahaffey KW. Sharma A, et al. Diabetes Obes Metab. 2024 Feb;26(2):758-762. doi: 10.1111/dom.15340. Epub 2023 Oct 26. Diabetes Obes Metab. 2024. PMID: 37881140 No abstract available.
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Verma S, Sharma A, Zinman B, Ofstad AP, Fitchett D, Brueckmann M, Wanner C, Zwiener I, George JT, Inzucchi SE, Butler J, Mazer CD. Verma S, et al. Among authors: sharma a. Diabetes Obes Metab. 2020 Jul;22(7):1141-1150. doi: 10.1111/dom.14015. Epub 2020 Mar 29. Diabetes Obes Metab. 2020. PMID: 32227432 Free PMC article. Clinical Trial.
Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HFDM ) in patients in the ACCORD trial.
Elharram M, Ferreira JP, Huynh T, Ni J, Giannetti N, Verma S, Zannad F, Sharma A. Elharram M, et al. Among authors: sharma a. Diabetes Obes Metab. 2021 Mar;23(3):782-790. doi: 10.1111/dom.14283. Epub 2021 Jan 5. Diabetes Obes Metab. 2021. PMID: 33269511
Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions - proceedings from the CEC Summit 2018.
Sharma A, Mahaffey KW, Gibson CM, Hicks KA, Alexander KP, Ali M, Chaitman BR, Held C, Hlatky M, Jones WS, Mehran R, Menon V, Rockhold FW, Seltzer J, Spitzer E, Wilson M, Lopes RD. Sharma A, et al. Am Heart J. 2022 Apr;246:93-104. doi: 10.1016/j.ahj.2021.12.012. Epub 2021 Dec 31. Am Heart J. 2022. PMID: 34973948 Free article.
23,145 results
You have reached the last available page of results. Please see the User Guide for more information.